
==== Front
Cardiovasc Endocrinol Metab
Cardiovasc Endocrinol Metab
CAEN
Cardiovascular Endocrinology & Metabolism
2574-0954
Wolters Kluwer Health

CAEN-D-24-00014
00001
10.1097/XCE.0000000000000310
3
Correspondence
The lifetime healthcare costs of female obesity: modeling of England data and the costs of current pharmacotherapy
Heald Adrian H. ab
Stedman Mike c
Warner-Levy John b
Whyte Martin B. d
Rutter Martin K. efg
Gibson John Martin ab
a The School of Medicine and Manchester Academic Health Sciences Centre, University of Manchester, Manchester
b Department of Diabetes and Endocrinology, Salford Royal NHS Foundation Trust, Salford
c RES Consortium, andover
d Department of Clinical and Experimental Medicine, University of Surrey, Guildford
e Division of Diabetes, Endocrinology and Gastroenterology, School of Medical Sciences, University of Manchester, Manchester
f Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust
g Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre and
Correspondence to Adrian H. Heald, DM, The School of Medicine and Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK, E-mail: adrian.heald@manchester.ac.uk
20 9 2024
12 2024
13 4 e003109 6 2024
3 9 2024
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

OPEN-ACCESSTRUE
==== Body
pmcObesity has major impacts on all-cause mortality risk, healthcare resource utilization (HCRU), [1] and quality of life [2]. It is associated with an increased risk of developing long-term conditions such as type 2 diabetes, cardiovascular disease, hypertension, and a number of cancers, while also being associated with premature death [3]. In women, obesity can adversely affect reproductive health, leading to obstetric and neonatal complications, as well as underpinning the development of breast and endometrial cancers [4].

Glucagon-like peptide-1 (GLP-1) receptor agonists and associated incretin therapies have been shown to lower body weight, improve cardiovascular outcomes, and lower blood glucose levels [5]. However, the affordability of these medications remains a concern for the National Health Service in the UK and elsewhere, given the constraints of limited resources. It is therefore important to estimate the lifetime health costs associated with obesity, as this will inform decision-making regarding the use of drugs such as GLP-1 agonists.

The numbers of men and women with Class I/II obesity in England are similar, but Class III obesity is twice as prevalent in women than men [6,7]—nearly 600 000 women under 50 years of age have Class III obesity [7]. We have here estimated the lifetime costs of medical care for women with Class I/II obesity and for Class III obesity, compared to those with a BMI of <25 kg/m2.

Regarding available pharmacotherapy to facilitate weight reduction (as distinct from lifestyle intervention programs), in the STEP 1 trial of adults, without diabetes, after 68 weeks 86.4% of the GLP-1 (semaglutide) group lost at least 5% on baseline weight, compared with 31.5% for placebo. Semaglutide led to 69.1% (vs. 12.0%) losing ≥10% weight (69.1 vs. 12.0%), and ≥20% reduction of baseline weight was achieved in 32.0 (vs. 1.7%) [8]. The SURMOUNT-1 trial found that in people with overweight/obese but without diabetes, 72 weeks of the combined GLP-1/glucose-dependent insulinotropic peptide (GIP) agonist, tirzepatide, at doses of 5, 10, or 15 mg led to 15.0, 19.5, and 20.9% weight loss, respectively, compared with 3.1% in people taking placebo [9]. For the co-primary endpoint of the proportion of people attaining at least a 5% reduction in their baseline bodyweight, the corresponding values were 85%, 89%, and 91% vs. 35% for placebo.

When examining the transition between established BMI categories, in the global medical literature, the proportions of trial entrants transitioning across BMI categories are not well reported, and so projections concerning transition between BMI categories are very challenging. While significant weight loss is achieved, many individuals with obesity or overweight are likely to require additional therapies if normalization of BMI to <25 kg/m2 was the goal [10].

In this context, we examined the female population in England split by age and BMI class, based on published data. Consequent life expectancy and HCRU costs (HCRU) [11] which include costs of treatment and hospitalization were calculated for each BMI class and compared to those with a BMI of <25 kg/m2. The relative health cost for individuals by BMI category was not reliably available for males, hence the female only focus here. The total HCRU (based on current costs) was added up over the future expected life years to give a total Lifetime HCRU (LT-HCRU). The association with obesity was then estimated both in total and per person, with adjustment for the loss of life years. As the increased HCRU due to BMI will occur at older age, lifetime costs capture this effect. However, the increased mortality and corresponding reduction in expected life years can offset this increase.

Table 1 shows the expected excess lifetime health costs at population level and per person vs. sex and age-matched individuals with BMI < 25 kg/m2. Derived from Table 1, females with BMI 30–39.9 kg/m2, representing 29% of the female adult population, lose 17.5 million expected life years with a net additional LT-HCRU of £9481/person, while females with BMI ≥ 40; 4.3% of this population, lose 6.1 million expected life years with additional LT_HCRU of +£8565/person; of these, the 2.6% aged 16–49 years lose 1 million expected life years with a net additional LT-HCRU costs of +£10 736/person.

Table 1 Nominal expected excess lifetime health costs at a population level and per person vs sex and age-matched Individuals with BMI < 25 kg/m2

	Population, 000	Average age (years)	Life expectancy (years)	Total lifetime HCRU (£ billion) summated for the population	Lifetime HCRU/person	
Overall	23 180	48.8	37.4	£2255	£97 322	
BMI 30–39.9 kg/m2	6744	51.6	32.7	£671	£99 520	
Difference to BMI < 25 kg/m2	−2.6	+£63	+£9481	
BMI ≥ 40 kg/m2	1101	46.3	33.8	£106	£105 445	
Difference to BMI < 25 kg/m2	−6.1	+£8.7	+£8565	
BMI ≥ 40 kg/m2 & age 16–49 years	595	34.9	43.4	£71	£120 605	
Difference to BMI < 25 kg/m2	−7.0	+£6.3	+£10 736	
HCRU, healthcare resource utilization.

In Figure 1 we have provided a breakdown by age band and BMI category for future life years lost per person and additional lifetime HCRU per person.

Fig. 1 Analysis of future life years lost and additional lifetime HCRU per person by BMI category and age band. BMI, body mass index; HCRU, healthcare resource utilization.

It has been reported that younger women are at the highest risk of being overweight [6,7]. Weight control programs, including, for example, a very low-calorie diet, are expensive and medication support such as GLP-1 agonists costs up to £1200/€1400 per year [12], with the long-term sustainability of both these approaches unpredictable at an individual level [10].

In the case of women with obesity, the direct estimated lifetime HCRU gains, as reported above, may not justify investment in weight-reducing pharmacotherapy. However, if 50% of life years lost could be avoided and a value of £30 000 associated with each life year gained, then the additional benefits for BMI ≥ 30 kg/m2 could be around £40 000/person; BMI ≥ 40 kg/m2 £90 000/person; and of those with BMI ≥ 40 kg/m2 and aged 16–49 years: £105 000/person.

In the light of this analysis, we suggest that the construction of financial cases for GLP-1 or other incretin therapy initiation and other treatment options over many years must also take into account the potential improvements in a person’s quality of life and improved survival, in order to provide sufficient evidence from a health economic perspective, for the benefit of these pharmacological interventions in the longer term.

Acknowledgements

M.S. undertook data assembly and data analysis with the help of J.W.-L. A.H. and M.S. conceived the study. J.W.-L. assisted with the collation of references as did M.B.W. M.B.W., J.M.G. and M.K.R. assisted with the interpretation of results. All authors were involved in interpreting the findings reviewing/editing of the manuscript.

The datasets analyzed during the current study are publicly available to anyone who wishes to access them.

As this study utilized already published publicly available or aggregated data for analysis, it was not felt that ethical approval was required.

Conflicts of interest

There are no conflicts of interest.
==== Refs
References

1 Tremmel M Gerdtham UG Nilsson PM Saha S . Economic burden of obesity: a systematic literature review. Int J Environ Res Public Health 2017; 14 :435.28422077
2 Søltoft F Hammer M Kragh N . The association of body mass index and health-related quality of life in the general population: data from the 2003 Health Survey of England. Qual Life Res 2009; 18 :1293–1299.19813103
3 Bhaskaran K Dos-Santos-Silva I Leon DA Douglas IJ Smeeth L . Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK. Lancet Diabetes Endocrinol 2018; 6 :944–953.30389323
4 Zheng L Yang L Guo Z Yao N Zhang S Pu P . Obesity and its impact on female reproductive health: unraveling the connections. Front Endocrinol (Lausanne) 2024; 14 :1326546.38264286
5 Sandsdal RM Juhl CR Jensen SBK Lundgren JR Janus C Blond MB . Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol 2023; 22 :41.36841762
6 Heald A Stedman M Fryer AA Davies MB Rutter MK Gibson JM Whyte M . Counting the lifetime cost of obesity: analysis based on national England data. Diabetes Obes Metab 2024; 26 :1464–1478.38312024
7 Obesity Prevalence by Age, sex and deprivation. NHS Digital Health Survey for England (HSE). https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2019. [Accessed 25 January 2024]
8 Wilding JPH Batterham RL Calanna S Davies M Van Gaal LF Lingvay I .; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021; 384 :989–1002.33567185
9 Jastreboff AM Aronne LJ Ahmad NN Wharton S Connery L Alves B .; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022; 387 :205–216.35658024
10 Caro R Samsel D Savel P . Is there sustained weight loss after discontinuation of GLP-1 agonist for obesity treatment? Evidence-Based Pract 2023; 26 :7–8.
11 Ward ZJ Bleich SN Long MW Gortmaker SL . Association of body mass index with health care expenditures in the United States by age and sex. PLoS One 2021; 16 :e0247307.33760880
12 Evans M Berry S Malkin SJP Hunt B Sharma A . Evaluating the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus liraglutide 1.8 mg: a health economic analysis in the UK. Diabetes Ther 2023; 14 :1005–1021.37120480
